Hanmi Pharmaceutical will unveil a large number of innovative new drug pipelines in the field of anticancer that have been greatly expanded at the American Association for Cancer Research (AACR 2023), which will be held in Orlando, Florida, from March 14 to 19.
In this AACR, Hanmi Pharm presented research results on two cases of LAPSIL-2 analog (HM16390), EZH1/2 double inhibitor (HM97662), SOS1 inhibitor (HM99462), YAP/TAZ-TEAD inhibitor, mRNA anti-cancer vaccine, and Beijing Hanmi Pharm.
On April 5, it was announced that a total of seven research results, including one PD-L1/4-1BB BsAb (BH3120) based on the bispecific antibody platform being actively developed, will be presented as posters.
On April 17, Hanmi Pharmaceutical will disclose the antitumor efficacy study results of its next-generation interleukin-2 (IL-2) immuno-oncology drug (HM16390).
IL-2 is a substance that differentiates/activates cytotoxic lymphocytes, and currently approved recombinant human IL-2 (aldesleukin) has serious side effects such as vascular leak syndrome when used in high doses for sufficient antitumor efficacy, which limits its use.
HM16390, which is being developed by Hanmi Pharmaceutical, is a candidate material that has improved safety as well as strong antitumor efficacy by optimizing the binding force between IL-2 receptors.
It is a formulation that can be administered subcutaneously once per anticancer cycle, and toxicity studies are currently underway to enter phase 1 clinical trials.
Along with this, Hanmi Pharmaceutical will announce on April 19 the results of a study confirming the strong anti-cancer effect of HM97662, an EZH1/2 dual inhibitor.
EZH2 is an enzyme that epigenetically methylates the lysine of a protein called histone. EZH2 mutations or dysfunctions of various proteins that control overexpressed EZH2 are known to cause various malignancies.
On April 17, Hanmi Pharmaceutical will announce the research results of HM99462, which targets the KRAS mutation, the most lethal of cancer-causing gene mutations. KRAS, a protein that plays an important role in cell growth, differentiation, proliferation, and survival, causes various mutations and causes lung cancer, colon cancer, and pancreatic cancer.
HM99462 under development is highly expected to be able to suppress resistance induction while enhancing the therapeutic effect on various carcinomas associated with KRAS activation through combination with existing drugs.
Hanmi Pharmaceutical also unveils a new YAP/TAZ-TEAD inhibitor for Hippo signaling pathway target solid cancer. Hippo signaling pathway in cells is known to play a role in regulating cell proliferation and homeostasis of stem cell function.
“Hanmi Pharm will continue to discover new innovative programs while further advancing existing R&D tasks," said an official from Hanmi Pharm. "Through the development of global innovative new drugs, we will not only increase the future value of Korea and the United States, but also focus our R&D capabilities on improving the lives of patients around the world suffering from diseases.”
